Business Context and Reporting Period
This Form 8-K was filed by Pluristem Therapeutics Inc. on June 27, 2013, reporting events occurring on June 26, 2013. The filing details a strategic partnership in South Korea regarding the company's PLX-PAD product for treating Critical Limb Ischemia and Intermediate Claudication.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The primary financial data relates to a specific transaction:
- Transaction Value: Approximately $10 million (based on the average closing price of CHA common shares over the last 30 trading days).
- Equity Issuance: Pluristem agreed to issue 2,500,000 shares of its common stock to CHA Bio&Diostech.
- Equity Receipt: Pluristem will receive 1,011,504 common shares of CHA.
Material Changes and Agreements
On June 26, 2013, a wholly owned subsidiary of Pluristem entered into an Exclusive License and Commercialization Agreement with CHA Bio&Diostech (CHA). Key terms include:
- Exclusive Rights: CHA receives exclusive rights in South Korea to conduct clinical trials for the specified indications at CHA's sole expense.
- Joint Venture: Upon regulatory approval in South Korea, the parties will form an equally owned joint venture to sell, distribute, and market the products.
- Intellectual Property: Pluristem retains all IP rights and will license them to the joint venture.
- Shareholder Restrictions: Both parties agreed to hold the received shares for at least one year and granted irrevocable proxies to the other party's management regarding voting power.
Outlook, Risks, and Contingencies
The execution of the agreement and the issuance of shares are contingent upon specific conditions:
- Lifting of a clinical hold by the U.S. Food and Drug Administration (FDA) on a study of one of the indications (previously reported on June 4, 2013).
- Reaching an agreed-upon development plan for conducting the clinical trials.
- Receipt of necessary regulatory approvals in South Korea.
Risks and Forward-Looking Statements: The filing warns that actual results may differ due to regulatory delays, failure to validate technology, scientific difficulties, inability to retain key employees, patent insufficiency, and market competition. Pluristem undertakes no obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the status of the FDA clinical hold mentioned as a condition for the agreement.
- Confirm the timeline for reaching the agreed-upon development plan with CHA.
- Review the full text of the Exclusive License and Commercialization Agreement once filed.
- Monitor the one-year lock-up period for the exchanged shares.
- Assess the regulatory pathway for PLX-PAD in South Korea for the specified indications.